

Supplementary Information (SI)

Design, synthesis, *in vitro* and *in vivo* evaluation of heterobivalent SiFAlin-coupled peptidic radioligands targeting both $\alpha_v\beta_3$ -integrin and MC1-receptor – Suitable for the specific visualization of melanomas?

Xia Cheng ¹, Ralph Hübner ², Valeska von Kiedrowski ¹, Gert Fricker ³, Ralf Schirmacher ⁴, Carmen Wängler ^{2,*} and Björn Wängler ^{1,*}

- ¹ Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
- ² Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
- ³ Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany
- ⁴ Department of Oncology, Division of Oncological Imaging, University of Alberta, 11560 University Avenue, Edmonton, T6G 1Z2, Alberta, Canada
- * Correspondence: Carmen.Waengler@medma.uni-heidelberg.de; Bjoern.Waengler@medma.uni-heidelberg.de

Table of Contents

1. HPLC chromatograms and mass spectra of the peptides 7–9 and the linker-modified peptides 10–21	1
2. NMR and mass spectra of SiFAlin 28 , SiFAlin-modified framework 29 and their intermediates 22–27	16
3. Mass and ¹⁹ F NMR spectra of HBPLs 1–6 and mass spectra of their intermediates 30–35	47
4. Mass data, HPLC chromatograms and mass spectra of peptidic side products a–z	65
5. Radio-HPLC chromatograms of [¹⁸ F] 1 –[¹⁸ F] 6 from the investigation regarding serum stability	93
6. Binding curves of the monomeric peptides c(RGDfK) and GG-Nle-c(DHfRWK)	93
7. <i>Ex vivo</i> biodistribution data of [¹⁸ F] 2 and [¹⁸ F] 4	94

1. HPLC chromatograms and mass spectra of the peptides 7–9 and the linker-modified peptides 10–21




Figure S1. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of GG-Nle-c(DHfRWK) (**7**).







Figure S2. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(RGDfK)-EGEGE (8).




Figure S3. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of EGE-GE-GG-Nle-c(DHfRWK) (**9**).




Figure S4. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of NHS-PEG₁-c(RGDfK) (10).




Figure S5. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of NHS-PEG₃-c(RGDfK) (**11**).




Figure S6. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of NHS-PEG₅-c(RGDfK) (12).




Figure S7. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of NHS-PEG₈-c(RGDfK) (**13**).




Figure S8. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-DIG-c(RGDfK) (**14**).




Figure S9. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-Ox-EGEGE-c(RGDfK) (**15**).




Figure S10. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of NHS-PEG₁-GG-Nle-c(DHfRWK) (16).




Figure S11. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of NHS-PEG₃-GG-Nle-c(DHfRWK) (17).







Figure S12. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of NHS-PEG₅-GG-Nle-c(DHfRWK) (**18**).




Figure S13. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of NHS-PEG₈-GG-Nle-c(DHfRWK) (**19**).




Figure S14. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-DIG-GG-Nle-c(DHfRWK) (**20**).




Figure S15. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of HO-Ox-EGEGE-GG-Nle-c(DHfRWK) (21).

2. NMR and mass spectra of SiFAlin 28, SiFAlin-modified framework 29 and their intermediates 22–27




Figure S16: ¹H NMR spectrum of ((4-Bromobenzyl)oxy)(*tert*-butyl)dimethylsilane (**22**).




Figure S17. ^{13}C NMR spectrum of ((4-Bromobenzyl)oxy)(*tert*-butyl)dimethylsilane (**22**).




Figure S18. Mass spectrum (**A**: FI) of ((4-Bromobenzyl)oxy)(*tert*-butyl)dimethylsilane (**22**).




Figure S19. ^1H NMR spectrum of Di-*tert*-butyl(4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)fluorosilane (**23**).




Figure S20. ¹³C NMR spectrum of Di-*tert*-butyl(4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)fluorosilane (**23**).




Figure S21. ^{19}F NMR spectrum of Di-*tert*-butyl(4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)fluorosilane (**23**).





Figure S22. Mass spectrum (**A**: FD) of Di-*tert*-butyl(4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)fluorosilane (**23**).




Figure S23. ^1H NMR spectrum of (4-(Di-*tert*-butylfluorosilyl)phenyl)methanol (**24**).




Figure S24. ^{13}C NMR spectrum of (4-(Di-*tert*-butylfluorosilyl)phenyl)methanol (**24**).




Figure S25. ^{19}F NMR spectrum of (4-(Di-*tert*-butylfluorosilyl)phenyl)methanol (**24**).




Figure S26. Mass spectra (**A**: FD, **B**: DART) of 4-(Di-*tert*-butylfluorosilyl)phenyl)methanol (**24**).




Figure S27. ^1H NMR spectrum of (4-(Bromomethyl)phenyl)di-*tert*-butylfluorosilane (**25**).




Figure S28. ^{13}C NMR spectrum of (4-(Bromomethyl)phenyl)di-*tert*-butylfluorosilane (**25**).




Figure S29. ^{19}F NMR spectrum of (4-(Bromomethyl)phenyl)di-*tert*-butylfluorosilane (**25**).





Figure S30. Mass spectrum (**A**: FD) of (4-(Bromomethyl)phenyl)di-*tert*-butylfluorosilane (**25**).




Figure S31. ¹H NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-4,4-diethoxy-*N,N*-dimethylbutan-1-aminium bromide (**26**).




Figure S32. ^{13}C NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-4,4-diethoxy-*N,N*-dimethylbutan-1-aminium bromide (**26**).




Figure S33. ^{19}F NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-4,4-diethoxy-*N,N*-dimethylbutan-1-aminium bromide (**26**).




Figure S34. Mass spectra (**A**: FD, **B** ESI) of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-4,4-diethoxy-*N,N*-dimethylbutan-1-aminium bromide (**26**).




Figure S35. ¹H NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-*N,N*-dimethyl-4-oxobutan-1-aminium bromide (**27**).




Figure S36. ¹³C NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-*N,N*-dimethyl-4-oxobutan-1-aminium bromide (**27**).




Figure S37. ^{19}F NMR spectrum of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-*N,N*-dimethyl-4-oxobutan-1-aminium bromide (**27**).




Figure S38. Mass spectra (**A**: FD, **B** ESI) of *N*-(4-(Di-*tert*-butylfluorosilyl)benzyl)-*N,N*-dimethyl-4-oxobutan-1-aminium bromide (**27**).




Figure S39. ¹H NMR spectrum of 3-Carboxy-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethylpropan-1-aminium bromide (**28**).




Figure S40. ¹³C NMR spectrum of 3-Carboxy-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethylpropan-1-aminium bromide (**28**).




Figure S41. ¹⁹F NMR spectrum of 3-Carboxy-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethylpropan-1-aminium bromide (**28**).




Figure S42. HPLC chromatogram (A) and mass spectra (B: ESI, C MALDI) of 3-Carboxy-*N*-(4-(di-*tert*-butylfluorosilyl)benzyl)-*N,N*-dimethylpropan-1-aminium bromide (28).




Figure S43. ¹H NMR spectrum of (S)-4-((6-Amino-5-(2-(bis(3-aminopropyl)amino)acetamido)-6-oxohexyl)amino)-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethyl-4-oxobutan-1-aminium bromide (**29**).




Figure S44. ¹³C NMR spectrum of (S)-4-((6-Amino-5-(2-(bis(3-aminopropyl)amino)acetamido)-6-oxohexyl)amino)-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethyl-4-oxobutan-1-aminium bromide (**29**).




Figure S45. ^{19}F NMR spectrum of (S)-4-((6-Amino-5-(2-(bis(3-aminopropyl)amino)acetamido)-6-oxohexyl)amino)-N-(4-(di-*tert*-butylfluorosilyl)benzyl)-N,N-dimethyl-4-oxobutan-1-aminium bromide (**29**).

3. Mass and ^{19}F -NMR spectra of HBPLs 1–6 and mass spectra of their intermediates 30–35




Figure S47. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFA/in-APG-PEG₁-c(RGDfK) (**30**).




Figure S48. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFAlin-APG-PEG₃-c(RGDfK) (31).




Figure S49. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFA/in-APG-PEG₅-c(RGDfK) (32).




Figure S50. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFAlin-APG-PEG₈-c(RGDfK) (33).




Figure S51. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFA/in-APG-DIG-c(RGDfK) (**34**).




Figure S52. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-Ox-EGEGE-c(RGDfK) (**35**).




Figure S53. ^{19}F NMR spectrum of SiFA/*in*-APG-PEG₁-c(RGDfK)/GG-Nle-c(DHfRWK) (**1**).




Figure S54. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-PEG₁-c(RGDfK)/GG-Nle-c(DHfRWK) (**1**).




Figure S55. ^{19}F NMR spectrum of SiFA/In-APG-PEG₃-c(RGDfK)/GG-Nle-c(DHfRWK) (**2**).




Figure S56. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFA/in-APG-PEG₃-c(RGDfK)/GG-Nle-c(DHfRWK) (**2**).




Figure S57. ^{19}F NMR spectrum of SiFAIn-APG-PEG₅-c(RGDfK)/GG-Nle-c(DHfRWK) (**3**).




Figure S58. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-PEG₅-c(RGDfK)/GG-Nle-c(DHfRWK) (**3**).




Figure S59. ^{19}F NMR spectrum of SiFAIin-APG-PEG₈-c(RGDfK)/GG-Nle-c(DHfRWK) (**4**).




Figure S60. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-PEG₈-c(RGDfK)/GG-Nle-c(DHfRWK) (**4**).




Figure S61. ^{19}F NMR spectrum of SiFA/*in*-APG-DIG-c(RGDfK)/GG-Nle-c(DHfRWK) (**5**).




Figure S62. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-DIG-c(RGDfK)/GG-Nle-c(DHfRWK) (**5**).




Figure S63. ^{19}F NMR spectrum of SiFAlin-APG-Ox-EGEGE-c(RGDfK)/GG-Nle-c(DHfRWK) (**6**).




Figure S64. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-Ox-EGEGE-c(RGDfK)/GG-Nle-c(DHfRWK) (**6**).

4. Mass data, HPLC chromatograms and mass spectra of peptidic side products a–z

HO-PEG₁-c(RGDfK) (**a**): MS (MALDI) m/z calcd for $C_{35}H_{54}N_9O_{12}$ $[M+H]^+$ 792.39, found: 792.16; HRMS (ESI) m/z calcd for $C_{35}H_{54}N_9O_{12}$ $[M+H]^+$ 792.3886, found 792.3890.

c(RGDfK)-PEG₁-c(RGDfK) (**b**): MS (MALDI) m/z calcd for $C_{62}H_{92}N_{18}O_{18}$ $[M]^+$ 1376.68, found: 1376.51; HRMS (ESI) m/z calcd for $C_{62}H_{94}N_{18}O_{18}$ $[M+2H]^{2+}$ 689.3491, found 689.3506; calcd for $C_{62}H_{93}N_{18}O_{18}$ $[M+H]^+$ 1377.6910, found 1377.6972.

HO-PEG₃-c(RGDfK) (**c**): MS (MALDI) m/z calcd for $C_{39}H_{61}N_9O_{14}$ $[M]^+$ 879.43, found: 879.54; HRMS (ESI) m/z calcd for $C_{39}H_{62}N_9O_{14}$ $[M+H]^+$ 880.4411, found 880.4407.

c(RGDfK)-PEG₃-c(RGDfK) (**d**): MS (MALDI) m/z calcd for $C_{66}H_{100}N_{18}O_{20}$ $[M]^+$ 1464.74, found: 1464.78; HRMS (ESI) m/z calcd for $C_{66}H_{101}N_{18}O_{20}$ $[M+H]^+$ 1465.7434, found 1465.7475.

HO-PEG₅-c(RGDfK) (**e**): MS (MALDI) m/z calcd for $C_{43}H_{70}N_9O_{16}$ $[M+H]^+$ 968.49, found: 968.19; HRMS (ESI) m/z calcd for $C_{43}H_{70}N_9O_{16}$ $[M+H]^+$ 968.4935, found 968.4941.

c(RGDfK)-PEG₅-c(RGDfK) (**f**): MS (MALDI) m/z calcd for $C_{70}H_{109}N_{18}O_{22}$ $[M]^+$ 1553.80, found: 1553.12; HRMS (ESI) m/z calcd for $C_{70}H_{110}N_{18}O_{22}$ $[M+2H]^{2+}$ 777.4016, found 777.4054; calcd for $C_{70}H_{109}N_{18}O_{22}$ $[M+H]^+$ 1553.7958, found 1553.8101.

HO-PEG₈-c(RGDfK) (**g**): MS (MALDI) m/z calcd for $C_{49}H_{82}N_9O_{19}$ $[M+H]^+$ 1100.57, found: 1100.24; HRMS (ESI) m/z calcd for $C_{49}H_{82}N_9O_{19}$ $[M+H]^+$ 1100.5721, found 1100.5722.

c(RGDfK)-PEG₈-c(RGDfK) (**h**): MS (MALDI) m/z calcd for $C_{76}H_{121}N_{18}O_{25}$ $[M+H]^+$ 1685.87, found: 1685.15; HRMS (ESI) m/z calcd for $C_{76}H_{121}N_{18}NaO_{25}$ $[M+H+Na]^{2+}$ 854.4318, found 854.4318; calcd for $C_{76}H_{121}N_{18}O_{25}$ $[M+H]^+$ 1685.8745, found 1685.8771.

HO-PEG₁-GG-Nle-c(DHfRWK) (**i**): MS (MALDI) m/z calcd for $C_{60}H_{86}N_{17}O_{15}$ $[M+H]^+$ 1284.65, found: 1284.15; HRMS (ESI) m/z calcd for $C_{60}H_{87}N_{17}O_{15}$ $[M+H]^{2+}$ 642.8278, found 642.8286; calcd for $C_{60}H_{86}N_{17}O_{15}$ $[M+H]^+$: 1284.6517, found 1284.6534.

c(DHfRWK)-Nle-GG-PEG₁-GG-Nle-c(DHfRWK) (**j**): MS (MALDI) m/z calcd for $C_{112}H_{157}N_{34}O_{24}$ $[M+H]^+$ 2362.21, found: 2362.06; HRMS (ESI) m/z calcd for $C_{112}H_{159}N_{34}O_{24}$ $[M+3H]^{3+}$ 788.4095, found 788.4087; calcd for $C_{112}H_{158}N_{34}O_{24}$ $[M+2H]^{2+}$ 1182.1105, found 1182.1107.

HO-PEG₃-GG-Nle-c(DHfRWK) (**k**): MS (MALDI) m/z calcd for $C_{64}H_{94}N_{17}O_{17}$ $[M+H]^+$ 1372.70, found: 1372.49; HRMS (ESI) m/z calcd for $C_{64}H_{94}N_{17}O_{17}$ $[M+H]^{2+}$ 686.3501, found 686.3624; calcd for $C_{64}H_{94}N_{17}O_{17}$ $[M+H]^+$ 1372.7008, found 1372.7041.

c(DHfRWK)-Nle-GG-PEG₃-GG-Nle-c(DHfRWK) (**l**): MS (MALDI) m/z calcd for $C_{116}H_{165}N_{34}O_{26}$ $[M+H]^+$ 2450.26, found: 2450.78; HRMS (ESI) m/z calcd for $C_{116}H_{166}N_{34}O_{26}$ $[M+2H]^{2+}$ 1226.1368, found 1226.1374.

HO-PEG₅-GG-Nle-c(DHfRWK) (**m**): MS (MALDI) m/z calcd for $C_{68}H_{101}N_{17}O_{19}$ $[M]^+$ 1459.75, found: 1459.03; HRMS (ESI) m/z calcd for $C_{68}H_{102}N_{17}O_{19}$ $[M+H]^+$ 1460.7532, found 1460.7528.

c(DHfRWK)-Nle-GG-PEG₅-GG-Nle-c(DHfRWK) (**n**): MS (MALDI) m/z calcd for $C_{120}H_{173}N_{34}O_{28}$ $[M+H]^+$ 2538.32, found: 2538.09; HRMS (ESI) m/z calcd for $C_{120}H_{175}N_{34}O_{28}$ $[M+3H]^{3+}$ 847.1111, found 847.1110; calcd for $C_{120}H_{174}N_{34}O_{28}$ $[M+2H]^{2+}$ 1270.1630, found 1270.1641.

HO-PEG₈-GG-Nle-c(DHfRWK) (**o**): MS (MALDI) m/z calcd for $C_{74}H_{114}N_{17}O_{22}$ $[M+H]^+$ 1592.83, found: 1592.11; HRMS (ESI) m/z calcd for $C_{74}H_{114}N_{17}O_{22}$ $[M+H]^+$ 1592.8319, found 1592.8321.

c(DHfRWK)-Nle-GG-PEG₈-GG-Nle-c(DHfRWK) (**p**): MS (MALDI) *m/z* calcd for C₁₂₆H₁₈₅N₃₄O₃₁ [*M*+H]⁺ 2670.39, found: 2670.33; HRMS (ESI) *m/z* calcd for C₁₂₆H₁₈₈N₃₄O₃₁ [*M*+4H]⁴⁺ 668.6048, found 668.6048; calcd for C₁₂₆H₁₈₇N₃₄O₃₁ [*M*+3H]³⁺ 891.1373, found 891.1372; calcd for C₁₂₆H₁₈₆N₃₄O₃₁ [*M*+2H]²⁺ 1336.2023, found 1336.2039.

c(RGDfK)-DIG-c(RGDfK) (**q**): MS (MALDI) *m/z* calcd for C₅₈H₈₅N₁₈O₁₇ [*M*+H]⁺ 1305.63, found: 1305.49; HRMS (ESI) *m/z* calcd for C₅₈H₈₆N₁₈O₁₇ [*M*+2H]²⁺ 653.3204, found 653.3207; calcd for C₅₈H₈₅N₁₈O₁₇ [*M*+H]⁺ 1305.6335, found 1305.6356.

c(RGDfK)-EGEGE-Ox-EGEGE-c(RGDfK) (**r**): MS (MALDI) *m/z* calcd for C₅₈H₈₅N₁₈O₁₇ [*M*+H]⁺ 2263.95, found: 2263.82; HRMS (ESI) *m/z* calcd for C₉₄H₁₃₆N₂₈O₃₈ [*M*+2H]²⁺ 1132.9796, found 1132.9793.

c(DHfRWK)-Nle-GG-DIG-GG-Nle-c(DHfRWK) (**s**): MS (MALDI) *m/z* calcd for C₁₀₈H₁₄₈N₃₄O₂₃ [*M*]⁺ 2289.15, found: 2289.51; HRMS (ESI) *m/z* calcd for C₁₀₈H₁₅₁N₃₄O₂₃ [*M*+3H]³⁺ 764.3903, found 764.3896; calcd for C₁₀₈H₁₅₀N₃₄O₂₃ [*M*+2H]²⁺ 1146.0818, found 1146.0820.

c(DHfRWK)-Nle-GG-EGEGE-Ox-EGEGE-GG-Nle-c(DHfRWK) (**t**): MS (MALDI) *m/z* calcd for C₁₄₄H₁₉₉N₄₄O₄₄ [*M*+H]⁺ 3248.47, found: 3248.29; HRMS (ESI) *m/z* calcd for C₁₄₄H₂₀₁N₄₄O₄₄ [*M*+3H]³⁺ 1083.8287, found 1083.8283; calcd for C₁₄₄H₂₀₀N₄₄O₄₄ [*M*+2H]²⁺ 1625.2394, found 1625.2388.

SiFalin-APG-[PEG₁-c(RGDfK)]₂ (**u**): MS (MALDI) *m/z* calcd for C₁₀₅H₁₆₉FN₂₅O₂₅Si [*M*]⁺ 2227.25, found: 2227.78; HRMS (ESI) *m/z* calcd for C₁₀₅H₁₇₁FN₂₅O₂₅Si [*M*+2H]³⁺ 743.4216, found 743.4216; calcd for C₁₀₅H₁₇₀FN₂₅O₂₅Si [*M*+H]²⁺ 1114.6288, found 1114.6282.

SiFalin-APG-[PEG₃-c(RGDfK)]₂ (**v**): MS (MALDI) *m/z* calcd for C₁₁₃H₁₈₆FN₂₅O₂₉Si [*M*+H]⁺ 2404.36, found: 2404.59; HRMS (ESI) *m/z* calcd for C₁₁₃H₁₈₇FN₂₅O₂₉Si [*M*+2H]³⁺ 802.1232, found 802.1231; calcd for C₁₁₃H₁₈₆FN₂₅O₂₉Si [*M*+H]²⁺ 1202.6812, found 1202.6806.

SiFalin-APG-[PEG₅-c(RGDfK)]₂ (**w**): MS (MALDI) *m/z* calcd for C₁₂₁H₂₀₂FN₂₅O₃₃Si [*M*+H]⁺ 2580.46, found: 2580.38; HRMS (ESI) *m/z* calcd for C₁₂₁H₂₀₄FN₂₅O₃₃Si [*M*+3H]⁴⁺ 645.8705, found 645.8709; calcd for C₁₂₁H₂₀₃FN₂₅O₃₃Si [*M*+2H]³⁺ 860.8249, found 860.8249; calcd for C₁₂₁H₂₀₂FN₂₅O₃₃Si [*M*+H]²⁺ 1290.7336, found 1290.7334.

SiFalin-APG-[PEG₈-c(RGDfK)]₂ (**x**): MS (MALDI) *m/z* calcd for C₁₃₃H₂₂₅FN₂₅O₃₉Si [*M*+H]⁺ 2843.61, found: 2843.59; HRMS (ESI) *m/z* calcd for C₁₃₃H₂₂₈FN₂₅O₃₉Si [*M*+3H]⁴⁺ 711.9098, found 711.9095; calcd for C₁₃₃H₂₂₇FN₂₅O₃₉Si [*M*+2H]³⁺ 948.8773, found 948.8771; calcd for C₁₃₃H₂₂₆FN₂₅O₃₉Si [*M*+H]²⁺ 1422.8123, found 1422.8132.

SiFalin-APG-[DIG-c(RGDfK)]₂ (**y**): MS (MALDI) *m/z* calcd for C₉₇H₁₅₃FN₂₅O₂₃Si [*M*]⁺ 2083.13, found: 2083.43; HRMS (ESI) *m/z* calcd for C₉₇H₁₅₀FN₂₅O₂₃Si [*M*-3H]⁺ 2081.1118, found 2081.4647.

SiFalin-APG-[Ox-EGEGE-c(RGDfK)]₂ (**z**): MS (MALDI) *m/z* calcd for C₁₃₁H₂₀₀FN₃₅O₄₃Si [*M*+H]⁺ 2998.43, found: 2998.28; HRMS (ESI) *m/z* calcd for C₁₂₃H₁₇₉N₃₅O₄₃ [*M*-C₇H₁₇FSi]⁺ 1417.6459, found 1417.6307.




Figure S65. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-PEG₁-c(RGDfK) (**a**).




Figure S66. HPLC chromatogram **(A)** and mass spectra **(B: ESI, C: MALDI)** of c(RGDfK)-PEG₁-c(RGDfK) **(b)**.




Figure S67. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of HO-PEG₃-c(RGDfK) (c).




Figure S68. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(RGDfK)-PEG₃-c(RGDfK) (d).




Figure S69. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of HO-PEG₅-c(RGDfK) (e).




Figure S70. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of c(RGDfK)-PEG₅-c(RGDfK) (**f**).




Figure S71. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-PEG₈-c(RGDfK) (**g**).




Figure S72. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(RGDfK)-PEG₈-c(RGDfK) (h).



Figure S73. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-PEG₁-GG-Nle-c(DHfRWK) (**i**).




Figure S74. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(DHfRWK)-Nle-GG-PEG₁-GG-Nle-c(DHfRWK) (j).




Figure S77. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of HO-PEG₅-GG-Nle-c(DHfRWK) (m).




Figure S78. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of c(DHfRWK)-Nle-GG-PEG₅-GG-Nle-c(DHfRWK) (**n**).




Figure S79. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of HO-PEG₈-GG-Nle-c(DHfRWK) (**o**).




Figure S81. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(RGDfK)-DIG-c(RGDfK) (q).




Figure S82. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of c(RGDfK)-EGEGE-Ox-EGEGE-c(RGDfK) (**r**).




Figure S83. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of c(DHfRWK)-Nle-GG-DIG-GG-Nle-c(DHfRWK) (**s**).




Figure S84. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of c(DHfRWK)-Nle-GG-EGEGE-Ox-EGEGE-GG-Nle-c(DHfRWK) (t).




Figure S85. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFA/in-APG-[PEG₁-c(RGDfK)]₂ (**u**).




Figure S86. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFalin-APG-[PEG₃-c(RGDfK)]₂ (**V**).




Figure S87. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFalin-APG-[PEG₅-c(RGDfK)]₂ (**W**).




Figure S88. HPLC chromatogram (**A**) and mass spectra (**B**: ESI, **C**: MALDI) of SiFAlin-APG-[PEG₈-c(RGDfK)]₂ (**x**).




Figure S89. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFAlin-APG-[DIG-c(RGDfK)]₂ (*y*).




Figure S90. HPLC chromatogram (A) and mass spectra (B: ESI, C: MALDI) of SiFAlin-APG-[Ox-EGEGE-c(RGDfK)]₂ (Z).

5. Radio-HPLC chromatograms of [^{18}F]-[^{18}F]-6 from the investigation regarding serum stability




Figure S91. Depiction of the radio-HPLC chromatograms for [^{18}F]-1 – [^{18}F]-6 at certain time points. **A** [^{18}F]-1; **B** [^{18}F]-2; **C** [^{18}F]-3; **D** [^{18}F]-4; **E** [^{18}F]-5; **F** [^{18}F]-6.

6. Binding curves of the monomeric peptides c(RGDfK) and GG-Nle-c(DHfRWK)




Figure S92. Depiction of the determined binding curves of c(RGDfK) on MC1R-positive B16F10-cells (**A**) and GG-Nle-c(DHfRWK) on $\alpha_3\beta_3$ -positive U87MG-cells (**B**). Values are depicted as mean ($n = 9$), error bars represent SD.

7. *Ex vivo* biodistribution data of [¹⁸F]2 and [¹⁸F]4

Table S1. Determined ID/g-values of *ex vivo* biodistribution data of [¹⁸F]2 and [¹⁸F]4. Values are given as mean (n = 3) ± SD.

Tissue	ID/g ([¹⁸ F]2) [%]				ID/g ([¹⁸ F]4) [%]			
	[¹⁸ F]2	NDP blocking	c(RGDyK) blocking	double blocking	[¹⁸ F]4	NDP blocking	c(RGDyK) blocking	double blocking
blood	0.99 ± 0.23	0.84 ± 0.12	1.14 ± 0.15	1.13 ± 0.10	0.59 ± 0.08	2.07 ± 0.94	0.83 ± 0.06	1.00 ± 0.15
spleen	2.73 ± 0.85	2.75 ± 0.55	0.94 ± 0.19	1.07 ± 0.32	1.79 ± 0.31	1.51 ± 0.15	1.71 ± 0.62	0.69 ± 0.10
liver	17.20 ± 6.58	14.88 ± 5.07	4.94 ± 1.39	8.50 ± 2.71	8.30 ± 2.77	5.16 ± 0.56	10.37 ± 3.65	4.04 ± 1.06
kidneys	13.24 ± 3.57	17.27 ± 2.08	12.09 ± 2.30	24.02 ± 6.34	7.72 ± 2.57	23.11 ± 4.97	21.35 ± 4.04	26.54 ± 6.59
pancreas	0.91 ± 0.29	0.80 ± 0.15	0.36 ± 0.04	0.55 ± 0.15	0.25 ± 0.08	0.52 ± 0.12	0.66 ± 0.19	0.32 ± 0.04
lung	2.89 ± 1.04	2.98 ± 0.87	1.07 ± 0.15	1.30 ± 0.36	3.45 ± 1.15	1.25 ± 0.06	2.75 ± 1.04	0.88 ± 0.14
heart	1.24 ± 0.36	1.06 ± 0.31	0.62 ± 0.09	0.93 ± 0.18	0.56 ± 0.19	0.73 ± 0.06	1.51 ± 0.57	0.52 ± 0.06
brain	0.18 ± 0.02	0.13 ± 0.03	0.13 ± 0.05	0.07 ± 0.01	0.10 ± 0.03	0.19 ± 0.07	0.07 ± 0.02	0.07 ± 0.01
bone	8.01 ± 3.48	9.74 ± 2.85	4.12 ± 0.73	4.47 ± 1.57	18.07 ± 6.02	4.61 ± 0.71	4.99 ± 0.71	2.99 ± 0.78
muscle	4.37 ± 2.58	1.37 ± 0.26	0.38 ± 0.04	0.34 ± 0.07	0.07 ± 0.02	0.63 ± 0.07	1.62 ± 0.42	2.58 ± 1.28
tail	37.99 ± 14.37	37.64 ± 8.67	68.98 ± 3.84	53.33 ± 12.82	25.29 ± 8.43	52.78 ± 5.59	44.27 ± 12.11	55.60 ± 7.12
B16F10 tumor	2.32 ± 0.49	1.83 ± 0.24	1.98 ± 0.18	1.14 ± 0.42	2.58 ± 0.86	1.33 ± 0.27	2.29 ± 0.24	2.49 ± 0.09
U87MG tumor	2.33 ± 0.46	3.19 ± 0.33	1.48 ± 0.12	1.00 ± 0.11	3.92 ± 1.31	2.53 ± 0.15	2.67 ± 0.66	0.90 ± 0.05
stomach	1.56 ± 0.29	1.52 ± 0.31	0.54 ± 0.04	0.54 ± 0.12	0.38 ± 0.13	1.03 ± 0.11	0.99 ± 0.16	0.42 ± 0.03
small intestine	2.46 ± 1.77	2.75 ± 0.36	0.75 ± 0.11	0.90 ± 0.23	0.07 ± 0.02	1.60 ± 0.26	1.46 ± 0.53	0.54 ± 0.08
colon	1.58 ± 0.44	1.44 ± 0.34	0.50 ± 0.07	0.63 ± 0.20	0.77 ± 0.26	0.96 ± 0.13	0.80 ± 0.32	0.42 ± 0.05

Table S2. Determined tumor-to-blood, tumor-to-muscle, tumor-to-liver, and tumor-to-kidney ratios of [^{18}F]2 and [^{18}F]4. Values are given as mean (n = 3) \pm SD. Asterisks indicate statistically significant values (*: p < 0.05, **: p < 0.01 and ***: p < 0.001).

Ratio	[^{18}F]2		[^{18}F]4	
	B16F10	U87MG	B16F10	U87MG
tumor/blood	2.42 \pm 0.73	2.40 \pm 0.67	4.36 \pm 1.37	5.08 \pm 0.75**
tumor/muscle	0.68 \pm 0.41	0.79 \pm 0.66	38.56 \pm 9.24**	45.72 \pm 8.62***
tumor/liver	0.16 \pm 0.11	0.14 \pm 0.03	0.36 \pm 0.23	0.39 \pm 0.14
tumor/kidneys	0.19 \pm 0.10	0.18 \pm 0.02	0.38 \pm 0.24	0.40 \pm 0.07**




Figure S93. Depiction of tumor uptake of [^{18}F]2 and [^{18}F]4 with the respective blocking substances. **A** [^{18}F]2 in B16F10 tumor; **B** [^{18}F]2 in U87MG tumor; **C** [^{18}F]4 in B16F10 tumor; **D** [^{18}F]4 in U87MG tumor. Values are depicted as mean (n = 3), error bars represent SD.